Intranasal oxytocin in obsessive-compulsive disorder.
A 55-year patient with obsessive-compulsive disorder showed clear improvement during 4 weeks of treatment with intranasal oxytocin compared to 4 weeks of intranasal placebo. This improvement was concurrent with the development of severe memory disturbances, supporting the amnestic properties of the peptide. However, the patient also developed psychotic symptoms and a marked decrease in plasma sodium and osmolality, which may have masked the obsessive symptomatology. This case highlights the need for careful monitoring in long-term oxytocin therapy.
D000281:Administration, Intranasal; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D009994:Osmolar Concentration; D010121:Oxytocin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011605:Psychoses, Substance-Induced / Q000209:etiology; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced
D010121:Oxytocin